Drugs / Rintatolimod

Trials 28 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT03599453 Jan 2019 → Sep 2020 triple-negative breast carcinoma Roswell Park Cancer Institute Completed No outcome recorded
Phase 13 trials
Phase 1 NCT04081389 Dec 2019 → May 2022 breast carcinoma in situ, triple-negative breast carcinoma Roswell Park Cancer Institute Completed No outcome recorded
Phase 1 NCT00000713 ? → Oct 1992 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00000735 ? → Feb 1990 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1/210 trials
Phase 1/2 NCT05756166 Feb 2024 → Apr 2025 female breast carcinoma, triple-negative breast carcinoma Roswell Park Cancer Institute Terminated No outcome recorded
Phase 1/2 NCT05927142 Jan 2024 → Apr 2026 overdue pancreatic ductal adenocarcinoma Joachim Aerts, MD PhD Recruiting No outcome recorded
Phase 1/2 NCT04379518 Nov 2020 → Mar 2023 COVID-19, cancer, hematopoietic and lymphoid cell neoplasm Roswell Park Cancer Institute Terminated No outcome recorded
Phase 1/2 NCT03734692 Jan 2019 → Jul 2024 overdue ovarian carcinoma Robert Edwards Active not recruiting No outcome recorded
Phase 1/2 NCT02432378 Sep 2015 → Jun 2025 ovarian cancer Roswell Park Cancer Institute Withdrawn No outcome recorded
Phase 1/2 NCT02151448 Jul 2014 → Feb 2019 malignant pancreatic neoplasm, malignant peritoneal mesothelioma, peritoneal carcinomatosis David Bartlett Completed No outcome recorded
Phase 1/2 NCT01545141 Oct 2012 → Apr 2016 colorectal carcinoma Roswell Park Cancer Institute Terminated No outcome recorded
Phase 1/2 NCT01591473 Apr 2012 → Sep 2014 influenza AIM ImmunoTech Inc. Terminated No outcome recorded
Phase 1/2 NCT01355393 Jul 2011 → Nov 2013 HER2 positive breast carcinoma, male breast carcinoma University of Washington Completed No outcome recorded
Phase 1/2 NCT01312389 Apr 2011 → May 2012 fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma Abramson Cancer Center at Penn Medicine Terminated No outcome recorded
Phase 210 trials
Phase 2 NCT07634094 Aug 2026 → Aug 2028 expected ovarian cancer Kalinski, Pawel, MD, PhD Not yet recruiting No outcome recorded
Phase 2 NCT05494697 Jun 2026 → Dec 2029 malignant pancreatic neoplasm AIM ImmunoTech Inc. Suspended No outcome recorded
Phase 2 NCT04093323 Nov 2024 → Apr 2025 Roswell Park Cancer Institute Terminated No outcome recorded
Phase 2 NCT05592418 Jun → Nov 2023 long COVID-19 AIM ImmunoTech Inc. Completed No outcome recorded
Phase 2 NCT04119830 Feb 2022 → Feb 2024 colorectal adenocarcinoma Roswell Park Cancer Institute Withdrawn No outcome recorded
Phase 2 NCT03899987 Nov 2019 → Apr 2027 expected prostate adenocarcinoma Roswell Park Cancer Institute Active not recruiting No outcome recorded
Phase 2 NCT03403634 Apr 2018 → Dec 2020 colorectal carcinoma, metastatic carcinoma Roswell Park Cancer Institute Completed No outcome recorded
Phase 2 NCT02615574 Mar 2016 → Jun 2018 colorectal cancer Pawel Kalinski Withdrawn No outcome recorded
Phase 2 NCT00035581 May 2001 → Sep 2005 HIV infectious disease AIM ImmunoTech Inc. Terminated No outcome recorded
Phase 2 NCT00035893 May 2001 → Aug 2006 HIV infectious disease AIM ImmunoTech Inc. Completed No outcome recorded
Phase 31 trial
Phase 3 NCT00215800 Dec 1998 → Feb 2004 myalgic encephalomeyelitis/chronic fatigue syndrome AIM ImmunoTech Inc. Completed No outcome recorded
Phase not applicable2 trials
NCT00001000 ? → Jan 1990 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
NCT00002269 HIV infectious disease HEM Research Completed No outcome recorded
Phase not stated1 trial
NCT00215813 myalgic encephalomeyelitis/chronic fatigue syndrome AIM ImmunoTech Inc. Temporarily not available No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 29 sources stand behind the page.

FieldValueCited text
Known as Rintatolimod “Patients were enrolled in phase I portion of the trial NCT02432378, and treated with intraperitoneal cisplatin, intraperitoneal rintatolimod (dsRNA, TLR3 ligand), and oral...” PMID 35046055 May 2022
18

“The study drugs are a combination of celecoxib (Celebrex®), Interferon-α2b (IFN), and rintatolimod (Ampligen®), or CKM.” NCT02615574

rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery” NCT01545141

NCT03599453

NCT05592418

NCT04379518

NCT04081389

NCT07634094

NCT05927142

NCT05494697

NCT01355393

NCT02151448

NCT03734692

NCT03899987

NCT04119830

NCT00215813

NCT05756166

NCT03403634

NCT04093323

Known as Ampligen “The study drugs are a combination of celecoxib (Celebrex®), Interferon-α2b (IFN), and rintatolimod (Ampligen®), or CKM.” NCT02615574
6

NCT01312389

NCT00000713

NCT00001000

NCT00002269

NCT00215800

NCT00000735

Known as atvogen “a single dose of atvogen (ampligen)” NCT00001000
Known as Poly I: Poly C12U “poly I:poly C12U (Ampligen®) 400 mg IV Twice Weekly Versus Placebo” NCT00215800
4

Poly I: Poly C12U (Rintatolimod)” NCT00215813

NCT00035893

NCT01591473

NCT00035581

Known as poly-l:poly-C12U “Ampligen (poly-l:poly-C12U), a Toll-like receptor 3 agonist.” NCT01312389
Known as rintatolimod (Ampligen) “rintatolimod (Ampligen®)” NCT02615574
Known as Rintatolimod (poly I : poly C12U) Rintatolimod (poly I : poly C12U)NCT05592418
Action Inhibit “In vitro studies of ampligen have shown it will inhibit HIV infection.” NCT00001000
Modality Oligonucleotide (other) “rintatolimod (dsRNA, TLR3 ligand)” PMID 35046055 May 2022
Route Intravenous “given ampligen by intravenous infusion” NCT00000713
Target TLR3 “selective TLR3 agonist” PMID 33119613 Oct 2020